Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.61 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.61 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.61 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL28235832 | 0.98 | ALDH1A1 (0.59) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL31226260 | 0.89 | ALDH1A1 (0.50) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL8374757 | 0.89 | TDP1 (0.53) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL16972863 | 0.86 | TDP1 (0.47) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL14203410 | 0.86 | TSHR (0.47) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL13591379 | 0.86 | TDP1 (0.47) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL7253320 | 0.86 | GPR35 (0.53) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL15783807 | 0.82 | TDP1 (0.44) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL10584469 | 0.81 | GPR35 (0.44) | TDP1TSHRALDH1A1HIF1ACYP3A4 | |
| SCHEMBL27628260 | 0.81 | GPR35 (0.44) | TDP1TSHRALDH1A1HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4175186-A | CYCLIZATION OF A NITROHALOBENZENE COMPOUND WITH A DIALKYDITHIOCARBAMIC ACID | THE ANSUL COMPANY (US) | 1979-11-20 | — | — | US | claimed |
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8318761-B2 | Substituted arylsulfonamides as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318761-B2 | Substituted arylsulfonamides as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318761-B2 | Substituted arylsulfonamides as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| EP-1951042-B1 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1951051-B1 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-03 | — | — | EP | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2007061694-A2 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| CN-1909909-A | 1-benzyl-5-piperazin-1-yl-3, 4 dihydro-1H-quinazolin-2-one derivatives and each of 1H-benzo (1,2,6) thiadiazin-2, 2-dioxide and 1, 4-dihydro-benzo (D) (1,3) oxazin-2-one derivatives as 5-hydroxytryptamine receptor (5-HT) modulators for the treatment of central nervous system diseases | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| EP-1677791-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-07-28 | — | — | US | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | TDP1 1556/4885TSHR 2627/4885ALDH1A1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.